Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held ...

Radiopharmaceutical maker Lantheus Holdings plans to acquire Life Molecular Imaging for $350 million in a bid to build up its ...

Johnson & Johnson is considering an acquisition of CNS drugmaker Intra-Cellular Therapies, according to anonymous sources ...

Tune Therapeutics raises $175M Series B for epigenetic editing, with hepatitis B drug Tune-401 in the clinic. NEA, Yosemite, ...

Nature journal publishes article suggesting embryo gene editing could prevent major diseases, sparking debate. Study by Peter ...

NeurIPS, the biggest AI research conference, turned Vancouver’s convention center into a battleground for wooing AI talent.

Biogen has made an offer to acquire its partner Sage Therapeutics, according to a Friday evening regulatory disclosure, ...

An FDA advisory committee on Friday voted 8 to 4 in favor of Japan-based Seikagaku's condoliase injection for the treatment ...

Repare Therapeutics pauses gynecologic cancer drugs lunresertib & camonsertib, shifts focus to early-stage assets RP-1664 & ...

Two biotechs emerged on Friday with assets from Keymed Biosciences, extending a proliferating trend of Western investors ...

Endpoints Weekly reports on iECURE's gene therapy success for OTC deficiency, FDA CDER director Patrizia Cavazzoni's departure, and Verdiva Bio's $411M launch with Sciwind assets.

T cell engagers are having a moment, much like antibody-drug conjugates have for the past two years. The cell-depleting ...